Enteropathy-associated T-cell lymphoma natural history, complications and prognosis

Revision as of 16:39, 27 January 2016 by Sowminya Arikapudi (talk | contribs)
Jump to navigation Jump to search

Enteropathy-associated T-cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Enteropathy-associated T-cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Enteropathy-associated T-cell lymphoma natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Enteropathy-associated T-cell lymphoma natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis

CDC on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis

Enteropathy-associated T-cell lymphoma natural history, complications and prognosis in the news

Blogs on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis

Risk calculators and risk factors for Enteropathy-associated T-cell lymphoma natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

Overview

Prognosis

  • Recurrences most frequent in the small intestine[1]
  • According to the Peripheral T-Cell Lymphoma Project, median overall survival is ten months, while median failure-free survival is only six months
  • The peripheral index for T-cell lymphoma is useful in defining prognosis for enteropathy-associated T-cell lymphoma
  • Among the most influential prognostic factors is bulky disease, defined by a tumor mass greater than 5 cm[2]
  • Autologous stem cell transplantation is feasible for selected patients with enteropathy-associated T-cell lymphoma and can yield durable disease control in a significant proportion of these patients
  • One study found a trend for better survival in patients transplanted in first complete or partial remission at four years (66% vs. 36%; P = .062)[3]

References

  1. Enteropathy-associated T-cell lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd5315/. Accessed on January 27, 2016
  2. Delabie J, et al. (July 2011). "Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project". Blood. 118 (148): 148. doi:10.1182/blood-2011-02-335216.


Template:WikiDoc Sources